- Home
- APTV vs RPRX Comparison
APTV vs RPRX Comparison
Compare APTV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APTV | RPRX |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 16.4B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | APTV | RPRX |
|---|---|---|
| Price | $78.54 | $39.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $93.56 | $45.75 |
| AVG Volume (30 Days) | 2.2M | ★ 3.3M |
| Earning Date | 02-02-2026 | 02-10-2026 |
| Dividend Yield | N/A | ★ 2.37% |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.30 | ★ 1.75 |
| Revenue | ★ $20,152,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $5.14 | $37.66 |
| Revenue Next Year | $3.87 | $2.34 |
| P/E Ratio | $63.44 | ★ $22.68 |
| Revenue Growth | 2.17 | ★ 3.70 |
| 52 Week Low | $47.19 | $29.66 |
| 52 Week High | $88.93 | $41.70 |
Technical Indicators
Market Signals| Indicator | APTV | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 49.50 |
| Support Level | $76.00 | $39.87 |
| Resistance Level | $88.93 | $40.58 |
| Average True Range (ATR) | 2.57 | 0.78 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 20.96 | 34.46 |
Price Performance
Historical ComparisonAbout APTV Aptiv PLC
Aptiv PLC signal and power solutions segment supplies components and systems that make up a vehicle's electrical system, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The operating segments are grouped on the basis of similar product, market and operating factors: Signal and Power Solutions, which includes complete electrical architecture and component products. advanced Safety and User Experience, which includes vehicle technology and services in advanced safety, user experience, and smart vehicle computing and software, as well as cloud-native software platforms, autonomous driving technologies, and DevOps tools. Eliminations and Other.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.